Hi, Tim Plaehn here.
Silver has become one of the best investments for both growth AND income.
I've just found one tiny fund that is now delivering up to 20% in annualized cash distributions….
And could deliver $1,170 every month for you.
However that's not all….
The share price has jumped 68% in just 5 months.
This is one of the rarest combinations I've seen in 20 years of analyzing investments.
Click here to see how this works.
But hurry: the next monthly payout hits soon.
To your income,
Tim Plaehn
Lead Income Strategist
P.S. This isn't physical silver. It's a simple ETF that trades like any stock. Buy once, collect monthly income.
3 Under-the-Radar GARP Stocks That Could Beat Big Tech
By Nathan Reiff. Article Posted: 3/7/2026.
Key Points
- So-called GARP stocks are those with growth potential but at a reasonable price, including the potential for appreciation while also trading at a competitive valuation.
- Interactive Brokers has a strong growth trajectory, driven by a 37% surge in client equity last year and about 1 million net new accounts, all while trading at a discount to the market-wide average.
- EQT is a competitive play for passive income investors seeking a combination of value and growth, while TJX has a rapid expansion plan, which also potentially presents a buy-the-dip opportunity.
- Special Report: The Biggest IPO Ever: Claim Your Stake Today
With mega-cap tech names dominating many equities conversations in recent quarters, investors may be looking for alternatives that offer a bit more breadth. So-called GARP stocks—named for their goal of delivering "growth at a reasonable price"—combine elements of both value and growth in a single investment.
Unlike the dominant tech names that have climbed sharply over the last year, GARP stocks tend to be more modestly sized, with lower valuations but strong potential for earnings and cash-flow growth across several fundamental metrics. Below are three companies that blend value and growth characteristics.
Big Growth With a Reasonable Valuation: Interactive Brokers
Have $500? Invest in Elon's AI Masterplan (Ad)
What if you could claim a stake in what's set to be the biggest IPO ever… starting with just $500?
Everyone is talking about Elon Musk's SpaceX IPO.
Click here to get the details and I'll show you how to claim your stake…Interactive Brokers Group Inc. (NASDAQ: IBKR) provides brokerage and trading services to both retail and professional investors and advisors. With a price-to-earnings (P/E) ratio of 31.22, IBKR leans toward the growth side of the spectrum.
Still, its P/E is below the broader market average of 37.72, which could make IBKR attractive to investors seeking growth at a reasonable price—particularly after any pullbacks.
On growth metrics, IBKR looks robust: analysts project roughly 9% earnings growth in the coming year and about 11% near-term upside potential. The company posted a fifth consecutive quarter with more than $1 billion in adjusted pre-tax income in the latest period, and annual revenues exceeded $6 billion for the year.
Much of that expansion reflects the addition of about 1 million net new accounts and larger client balances—client equity rose 37% year-over-year in 2025, to $780 billion. With continued product rollouts (including AI features) and expansion into new markets likely in 2026, IBKR may sustain its growth trajectory. Investors should, however, watch interest-rate trends closely, since rate moves can materially affect trading activity and Interactive Brokers' results.
Strong Cash Flow and a Dividend for a Natural Gas Producer
An upstream energy company focused on natural gas, EQT Corp. (NYSE: EQT) can appeal to income-seeking investors with a dividend yield of 1.08% and a payout ratio comfortably below 20%.
That shareholder return is supported by rising production—driven in part by compression projects and lower well costs—robust cash generation and strategic acquisitions, all amid stronger energy demand from data centers that is benefitting natural gas producers.
With $2.5 billion in free cash flow in the latest quarter, EQT has the flexibility to increase investments in core assets like the Mountain Valley Pipeline and to allocate about $600 million toward updating compression and water systems to boost efficiency. The company's strong cash position also supports continued debt reduction.
EQT's P/E ratio of 18.52 is below the average for the energy sector, notable given that shares have risen nearly 23% over the past year. Its price-to-book (P/B) ratio of 1.38 is competitive as well. With Wall Street expecting earnings to rise roughly a third in the coming year and about 8% upside in the shares, investors may find the company's Moderate Buy rating justified.
TJX: Solid Results, a Brief Dip Opportunity After Slowing Comps
TJX Companies Inc. (NYSE: TJX) is an off-price retailer operating brands such as T.J. Maxx, Marshalls and HomeGoods. The company reported a strong Q4 fiscal 2026 (period ended Jan. 31, 2026), including a 16% year-over-year increase in adjusted earnings per share and plans to open about 146 net new stores in the coming fiscal year.
Shares fell briefly after management signaled that comparable-sales growth might slow to 2–3% in fiscal 2027, down from 5% in the most recent year.
Even so, TJX shows several positive indicators: disciplined inventory management, resilience amid tariff uncertainty, and a history of execution that helped drive a 33% improvement in the stock over the past year. Analysts look for roughly 10% earnings growth and a few additional percentage points of upside. With a price-to-sales (P/S) ratio of 2.97, TJX could offer a buy-on-a-dip opportunity for investors seeking a blend of value and growth.
Eli Lilly's Employer Push Could Unlock New GLP-1 Demand
Submitted by Leo Miller. Published: 3/15/2026.
Key Points
- Eli Lilly is opening up a new way for employers to cover their weight-loss drugs.
- With half or more of employees not having coverage for obesity medications, Employer Connect could unlock significant demand for LLY.
- Meanwhile, the company's oral GLP-1 just beat out Novo's in a head-to-head type 2 diabetes duel.
- Special Report: The Biggest IPO Ever: Claim Your Stake Today
The world’s most valuable pharmaceutical stock, Eli Lilly and Company (NYSE: LLY), continues to assert its dominance in the weight-loss and diabetes drug market in 2026.
The company’s most recent earnings report projected robust 25% growth for the year, well above expectations. While that pace would be slower than the 45% growth Lilly generated in 2025, it would still mark the company’s third-highest annual growth rate on record. The firm’s current GLP-1 franchises are expected to keep driving sales, but growth cannot remain at such elevated levels indefinitely.
Have $500? Invest in Elon's AI Masterplan (Ad)
What if you could claim a stake in what's set to be the biggest IPO ever… starting with just $500?
Everyone is talking about Elon Musk's SpaceX IPO.
Click here to get the details and I'll show you how to claim your stake…At the same time, Lilly’s top competitor, Novo Nordisk A/S (NYSE: NVO), is projecting its weakest revenue growth in years. For 2026, Novo expects sales to decline by between 5% and 13%. When measured in U.S. dollars, the company has not experienced a revenue drop of more than 5% since 2014; measured in Danish kroner, the last comparable decline occurred in 1998.
This contrast highlights Lilly’s relatively stronger position, particularly for the currently available injectable GLP-1s.
At the same time, the healthcare company is taking steps to extend that lead. Expanding drug access and winning the oral GLP-1 race are two key levers Lilly is pursuing.
Employer Connect: Lilly’s Bid to Close a Large Employer Coverage Gap
One of Lilly’s most significant recent moves is the launch of its Employer Connect platform. The program aims to close a gap in employer-sponsored obesity coverage: Lilly notes that roughly half of people on employer plans lack coverage for obesity treatment. One survey found that just 20% of companies with more than 200 workers cover weight-loss drugs, while only 43% of firms with 5,000 or more employees do so.
This represents a significant untapped opportunity for Lilly. If employers do not provide coverage, employees must pay out of pocket. Through LillyDirect, the company’s direct-to-consumer platform, Zepbound costs between $299 and $449 per month, a price that likely puts the medicine out of reach for many without employer support.
To address this, Lilly is offering Zepbound to employers at a discounted price of $449, with employees responsible for only a small portion of the cost. That price is less than half of the drug’s list price of over $1,000. Employer Connect also bypasses traditional pharmacy benefit managers (PBMs), which act as middlemen between drug companies and insurers and often have opaque pricing arrangements. The PBM industry is highly concentrated and wields substantial negotiating leverage.
Through Employer Connect, participating employers can choose from more than 15 independent program administrators and pick the option that best fits their needs. Lilly expects these administrators to compete on the services they provide.
If employers adopt the program at scale, Lilly could meaningfully grow Zepbound sales. However, any sizable contribution to revenue may not materialize until 2027 as employers evaluate the new option.
There is also a trade-off: if employers that already cover Zepbound switch to Employer Connect, Lilly could face downward pressure on price. Given the large coverage gap, the company appears willing to accept lower unit prices in exchange for a substantial increase in volume.
Lilly Wins a Head-to-Head in the Smaller Oral Type 2 Diabetes Market
Lilly also reported encouraging results for its developmental oral GLP-1, orforglipron. In a head-to-head trial, orforglipron outperformed Novo’s approved oral GLP-1, oral semaglutide, producing greater reductions in blood sugar and body weight in patients with type 2 diabetes. (Oral semaglutide has been marketed as Rybelsus since 2019.)
In the trial, A1C—a key blood sugar marker—fell by 2.2% for patients taking orforglipron versus 1.4% for those on oral semaglutide. Patients on orforglipron also lost 9.2% of their body weight, compared with 5.3% for oral semaglutide.
These results strengthen Lilly’s case for approval of orforglipron as an oral type 2 diabetes treatment. Still, the oral type 2 diabetes market is relatively small compared with the broader GLP-1 opportunity: Novo’s Rybelsus generated roughly $3.5 billion in sales in 2025, versus about $32.5 billion combined for Ozempic and Wegovy that year. Lilly is also pursuing approval of orforglipron as an oral obesity medication, which could address a much larger market.
LLY Keeps Opening New Doors to Drive Potential Growth
Overall, Lilly continues to expand potential customer bases by broadening access and advancing new products. While Lilly has already grown into a giant company, its track record of execution and focus on innovation make it a difficult stock to bet against.
to bring you the latest market-moving news.
This email message is a sponsored message provided by Investors Alley, a third-party advertiser of TickerReport and MarketBeat.
Contact Us | Unsubscribe
© 2006-2026 MarketBeat Media, LLC dba TickerReport.
345 N Reid Place, Sixth Floor, Sioux Falls, S.D. 57103-7078. U.S.A..
0 Response to "Silver paying 20% dividend. Plus 68% share gains"
Post a Comment